一种新型外用类固醇“哈西奈德”与氢化可的松在类固醇反应性皮肤病中的临床比较评估。

A comparative clinical evaluation of a new topical steroid 'halcinonide' and hydrocortisone in steroid-responsive dermatoses.

作者信息

Fattah A A, El-Shiemy S, Faris R, Tadros S S

出版信息

J Int Med Res. 1976;4(4):228-31. doi: 10.1177/030006057600400403.

Abstract

Fifty patients with symmetrical, bilateral lesions of psoriasis, eczematous dermatitis, atopic dermatitis, or neurodermatitis participated in a double-blind paired comparison study in which 0-1% halcinonide (in a cream formulation containing also neomycin and nystatin) was applied to the lesions on one side of the body and 1% hydrocortisone cream to those on the opposite side for two to three weeks. The number of excellent responses to therapy showed the halcinonide combination to be significantly superior (p less than 0-01) to the control cream in all diagnostic categories if considered collectively, and in psoriasis if the responses were grouped according to diagnosis. No adverse reactions occurred during the trial.

摘要

五十名患有对称性双侧病变的银屑病、湿疹性皮炎、特应性皮炎或神经性皮炎患者参与了一项双盲配对比较研究。在该研究中，将0 - 1%哈西奈德（于一种还含有新霉素和制霉菌素的乳膏制剂中）涂抹于身体一侧的病变部位，而将1%氢化可的松乳膏涂抹于身体另一侧的病变部位，持续两至三周。如果将所有诊断类别综合考虑，治疗产生的优效反应数量表明哈西奈德组合在所有诊断类别中均显著优于对照乳膏（p小于0.01）；如果根据诊断对反应进行分组，则在银屑病方面也是如此。试验期间未发生不良反应。